SCHEMBL5409335

SCHEMBL5409335

CN(C)CC(c1ccc(Cl)cc1)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
STS P08842 2/20 0.48
HTT P42858 2/20 0.48
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP3A4 P08684 2/20 0.47
CYP3A5 P20815 2/20 0.47
NPSR1 Q6W5P4 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
CNR1 P21554 3/20 0.45
MGLL Q99685 2/20 0.45
ABHD6 Q9BV23 1/20 0.45
VEGFA P15692 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
USP2 O75604 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14593442 0.89 MEN1 (0.50) MEN1KMT2ASTSHTTALDH1A1
SCHEMBL14593425 0.87 CYP3A4 (0.48) MEN1KMT2ASTSHTTALDH1A1
SCHEMBL5417860 0.86 MEN1 (0.54) MEN1KMT2ASTSHTTALDH1A1
SCHEMBL14593424 0.82 MC4R (0.47) MEN1KMT2ASTSHTTALDH1A1
SCHEMBL17276580 0.81 MGLL (0.64) MEN1KMT2ASTSHTTALDH1A1
SCHEMBL23532403 0.80 MEN1 (0.53) MEN1KMT2ASTSHTTALDH1A1
SCHEMBL14593446 0.78 MC4R (0.47) MEN1KMT2AHTTALDH1A1NPC1
SCHEMBL12371643 0.78 MEN1 (0.56) MEN1KMT2ASTSHTTALDH1A1
SCHEMBL23532387 0.78 MEN1 (0.53) MEN1KMT2ASTSHTTALDH1A1
SCHEMBL14088769 0.78 MAPT (0.47) MEN1KMT2ASTSHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230064189-A1 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-03-02 US disclosed
US-7169777-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-01-30 US disclosed
US-7169777-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-01-30 US disclosed
US-20040116699-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-06-17 US disclosed
EP-1358163-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-11-05 EP disclosed
WO-2002059095-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064189-A1 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER DPYD, ABCC1, TYMP MEN1 1923/4885KMT2A 2582/4885STS 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.